A new indicator of favorable prognosis in locally advanced renal cell carcinomas: γδ T-cells in peripheral blood

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 1027-1031

  Kobayashi, Hirohito ^a   Tanaka, Yoshimasa ^b   Nakazawa, Hayakazu ^c   Yagi, Junji ^a   Minato, Nagahiro ^b   Tanabe, Kazunari ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Gamma delta T cell; Prognosis factor; Renal cell carcinoma

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CAUSE SPECIFIC SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; CARCINOMA, RENAL CELL; DEMOGRAPHY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; YOUNG ADULT;

EID: 79956083387     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N and Toma H: Safety profile and anti-tumor effects of adoptive immunotherapy using γδ T-cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56: 469-476, 2007. (Pubitemid 46204533)
2. Wilhelm M, Kunzmann V, Eckstein S, S Reimer P, Weissinger F, Ruediger T and Tony HP: γδ T-Cells for immune therapy of patients with lymphoid malignancies. Blood 102: 200-206, 2003.
3. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, Salerno A, Eberl M and Hayday AC: Targeting human γδ T-cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67: 7450-7457, 2007.
4. Kobayashi H, Tabaka Y, Shimmura H, Minato N and Tanabe K: Complete remission of lung metastasis following adoptive immunotherapy using activated autologous γδ T-cells in a patients with renal cell carcinoma. Anticancer Res 30: 575-579, 2010.
5. Kato Y, Tanaka Y, Miyagawa F, Yamashita S and Minato N: Targeting of tumor cells for human γδ T-cells by nonpeptide antigens. J Immunol 167: 5092-5098, 2001. (Pubitemid 33009743)
6. Kobayashi H, Tanaka Y, Yagi J, Toma H and Uchiyama T: γδ T-cells provide innate immunity against renal cell carcinoma. Cancer Immunol Immunother 50: 115-124, 2001. (Pubitemid 32480555)
7. Chae EJ, Kim JK, Kim SH, Bae SJ and Cho KS: Renal cell carcinoma: analysis of postoperative recurrence patterns. Radiology 234: 189-196, 2005.
8. Tanaka Y: Human γδ T-cells and tumor immunotherapy. J Clin Exp Hematop 46: 11-23, 2006.
9. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R and Finke JH: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15: 2148-2157, 2009.
10. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R and Bukowski R: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14: 6674-6682, 2008.